Efficacy of Two Vaccine Platforms against SARS-CoV-2
-
Published:2022-12-01
Issue:2
Volume:9
Page:18-23
-
ISSN:1727-3706
-
Container-title:Vaccine Research
-
language:en
-
Short-container-title:vacres
Author:
ghazavi Ali, khaki Mohsen, Mosayebi Ghasem, Keshavarzian Nafiseh, Navabi Parnian, Ganji AliORCID
Publisher
Apex Publishing
Reference28 articles.
1. 1. Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, Fotiou D, Migkou M, Tzanninis I-G et al. Emerging treatment strategies for COVID-19 infection. Clinical and experimental medicine. 2021;21(2):167-79. 2. 2. Dicks MD, Spencer AJ, Edwards NJ, Wadell G, Bojang K, Gilbert SC et al. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PloS one. 2012;7(7):e40385. 3. 3. Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccine strategies. Nature Reviews Immunology. 2020;20(10):615-32. 4. 4. Yu S, Chen K, Fang L, Mao H, Lou X, Li C et al. Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans. Vaccines. 2021;9(6):588. 5. 5. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS et al. Gam-COVID-Vac Vaccine Trial Group Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671-81.
|
|